Author

L. Stuani

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 5 Approach:experimental assay· 5 Organism:human· 5 Assay:bulk RNA-seq· 4 Research Focus:cell type annotation· 4 Research Focus:differential expression· 3 Research Focus:drug response / drug discovery· 3 Approach:statistical model· 2

Frequent Co-Authors

J.-E. Sarry· 4 shared C. Bosc· 2 shared C. Larrue· 2 shared C. Recher· 2 shared E. Boet· 2 shared E. Saland· 2 shared F. Vergez· 2 shared J. Tamburini· 2 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

J.-E. Sarry

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Inosine Induces Stemness Features in CAR T cells and Enhances Potency

D. D. Klysz, C. Fowler, M. Malipatlolla, L. Stuani, K. A. Freitas, S. Meier, B. Daniel, K. Sandor, P. Xu, J. Huang, L. Labanieh, A. Leruste, M. Bashti, V. Keerthi, J. Mata-Alcazar, , C. L. Mackall

This study shows that inosine enhances CAR T cell stemness and function by modulating metabolism and epigenetics, leading to improved anti-tumor potency.

bioRxiv · Apr 21, 2023Immunology

Cytidine deaminase regulates mitochondrial biogenesis in pancreatic cancer cells

A. Frances, A. Lumeau, L. Stuani, M. Gayral, E. Salland, N. Bery, D. Pagan, N. Hanoun, J. Torrisani, A. Lemarie, J.-C. Portais, L. Buscail, N. Dusetti, J.-E. Sarry, P. Cordelier

This study shows that Cytidine deaminase (CDA) promotes mitochondrial biogenesis and oxidative phosphorylation in pancreatic cancer cells, independent of its deaminase activity, revealing new therapeutic targets.

bioRxiv · Dec 15, 2022 · PreprintCancer Biology

Mitochondrial determinants of response and resistance to venetoclax plus cytarabine duplet therapy in acute myeloid leukemia

C. Bosc, N. Gadaud, A. Bousard, M. Sabatier, G. Cognet, E. Saland, T. Farge, E. Boet, M. Gotanegre, N. Aroua, P.-L. Mouchel, C. Larrue, L. Jarrou, F. Rambow, F. Cabon, , J.-E. Sarry

This study identifies mitochondrial determinants of response and resistance to venetoclax plus cytarabine therapy in AML, showing that OxPHOS is a predictive marker and that targeting ETCI improves outcomes.

bioRxiv · Aug 17, 2020 · PreprintCancer Biology

Adrenomedullin-CALCRL Axis Controls Relapse-Initiating Drug Tolerant Acute Myeloid Leukemia Cells

C. Larrue, N. Guiraud, P.-L. Mouchel, M. Dubois, T. Farge, M. Gotanegre, C. Bosc, E. Saland, M.-L. Travers-Nicolau, M. Sabatier, N. Serhan, A. Sahal, E. Boet, S. Mouche, Q. Heydt, , J.-E. Sarry

The paper identifies the ADM-CALCRL axis as a driver of drug-tolerant AML cells that persist after chemotherapy and proposes it as a therapeutic target to prevent relapse.

bioRxiv · Aug 17, 2020Cancer Biology

Combinatory therapy targeting mitochondrial oxidative phosphorylation improves efficacy of IDH mutant inhibitors in acute myeloid leukemia

L. Stuani, J.-E. Sarry

This study shows that combining mitochondrial oxidative phosphorylation inhibitors with IDH mutant inhibitors improves anti-AML efficacy in IDH-mutant AML patients, especially those who relapse or are unresponsive.

bioRxiv · Aug 28, 2019Cancer Biology